INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaJérôme Fayette, Helena Rebelo‐de‐Andrade, Makoto Tahara et al.|Clinical Cancer Research|2025Cited by 26
Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapyCheng‐Ying Chu, Hsing‐Jien Kung, Yi‐Ching Lee et al.|Theranostics|2021Cited by 22
Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaJérôme Fayette, Jan Paul de Boer, Lisa Licitra et al.|Unknown|2025Cited by 0